- Home
- MIST
as 05-09-2025 3:39pm EST
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
| Founded: | 2003 | Country: | Canada |
| Employees: | N/A | City: | MONTREAL |
| Market Cap: | 53.9M | IPO Year: | N/A |
| Target Price: | $9.50 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.67 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.63 - $2.75 | Next Earning Date: | 05-20-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Milestone Pharmaceuticals Inc. News
MIST Breaking Stock News: Dive into MIST Ticker-Specific Updates for Smart Investing
Zacks
a month ago
MIST Stock Falls 66% Following Complete Response Letter for Cardamyst
TipRanks
a month ago
Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen
Investing.com
a month ago
TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty
MT Newswires
a month ago
HC Wainwright Adjusts Price Target on Milestone Pharmaceuticals to $10 From $25, Maintains Buy Rating
MT Newswires
a month ago
TD Cowen Downgrades Milestone Pharmaceuticals to Hold From Buy
TipRanks
a month ago
Milestone CRL affirms integrity of clinical data, says H.C. Wainwright
MT Newswires
a month ago
Top Midday Decliners
MT Newswires
a month ago
Sector Update: Health Care Stocks Mixed Friday Afternoon
Compare MIST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MIST Milestone Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.